Loading news...
Rapt Therapeutics (NASDAQ: RAPT - Get Free Report)'s share price reached a new 52-week high on Friday. The company traded as high as $57.74 and last traded at $57.74, with a volume of 1321908 shares trading hands. The stock had previously closed at $57.63. Wall Street Analysts Forecast Growth Several equities research analysts have recently
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Shareholders should contact the firm as there may be limited time to enforce your rights Shareholders should contact the firm as there may be limited time to enforce your rights
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics, Inc. (NasdaqGM: RAPT) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of RAPT will receive $58.00 in cash for each share of RAPT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.
GSK agrees to buy RAPT Therapeutics for $2.2B, adding ozureprubart to its pipeline and strengthening its respiratory and immunology portfolio.
Market sentiment declined as Trump's trade stance intensified fears. CNN Fear and Greed index moved to 'Neutral' zone.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
GSK offered to buy Rapt Therapeutics for a sizable premium to its recent market value. Rapt's experimental antibody therapy could help millions of people who suffer from severe food allergies.
BALA CYNWYD, Pa., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
NEW YORK, Jan. 20, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating RAPT Therapeutics, Inc. (NASDAQ: RAPT) related to its sale to GSK plc.
NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE: GSK) has entered into a definitive agreement to acquire Forbion Growth Fund III portfolio company RAPT Therapeutics, Inc. (NASDAQ: RAPT) in a transaction valued at $2.2 billion.
MILWAUKEE, Jan. 20, 2026 /PRNewswire/ -- Ademi LLP is investigating RAPT (NASDAQ: RAPT) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
The Dow Jones Industrial Average (DJI) is off 600 points as geopolitical tensions continue to kick off between U.S. and Europe
Major stock indexes sank Tuesday after President Donald Trump threatened to impose new tariffs on eight NATO allies for opposing his desired sale of Greenland to the U.S.
Shares of RAPT Therapeutics surged sharply on Tuesday after the biopharmaceutical company said it had agreed to be acquired by British drugmaker GSK in a deal valued at about $2.2 billion, giving the larger group access to a late-stage food allergy treatment. RAPT stock jumped 64% to $57.
US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adults
Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest rates.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of RAPT Therapeutics, Inc. (NASDAQ: RAPT) to GSK plc for $58.00 per share is fair to RAPT shareholders. Halper Sadeh encourages RAPT shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether RAPT and its board of directors.
GSK plc to acquire RAPT Therapeutics Inc. for $58.00 per share, with an estimated upfront investment of $1.9 billion.
GSK said on Tuesday that it would acquire U.S.-based RAPT Therapeutics for $2.2 billion.